Better Therapeutics, Inc.
BTTX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -55.6% | – |
| Cost of Goods Sold | $3 | $2 | $1 | $1 |
| Gross Profit | -$3 | -$2 | -$1 | -$1 |
| % Margin | – | – | -8,425% | -4,888.9% |
| R&D Expenses | $16 | $19 | $3 | $2 |
| G&A Expenses | $15 | $9 | $2 | $2 |
| SG&A Expenses | $22 | $11 | $3 | $3 |
| Sales & Mktg Exp. | $7 | $2 | $0 | $0 |
| Other Operating Expenses | -$3 | -$2 | $0 | $0 |
| Operating Expenses | $36 | $29 | $6 | $5 |
| Operating Income | -$38 | -$31 | -$6 | -$6 |
| % Margin | – | – | -79,037.5% | -32,072.2% |
| Other Income/Exp. Net | -$1 | -$10 | $0 | -$0 |
| Pre-Tax Income | -$40 | -$40 | -$6 | -$6 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$40 | -$40 | -$6 | -$6 |
| % Margin | – | – | -79,837.5% | -32,194.4% |
| EPS | -1.69 | -1.71 | -1.04 | -0.25 |
| % Growth | 1.2% | -64.4% | -316% | – |
| EPS Diluted | -1.69 | -1.71 | -1.04 | -0.25 |
| Weighted Avg Shares Out | 24 | 24 | 8 | 24 |
| Weighted Avg Shares Out Dil | 24 | 24 | 8 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $2 | $0 | $0 |
| EBITDA | -$38 | -$39 | -$6 | -$6 |
| % Margin | – | – | -75,737.5% | -31,672.2% |